Novo Nordisk– tag –
-
China’s Ascletis Initiates Global Phase III for Oral GLP-1 Obesity Drug ASC30, Preclinical Triple Agonist FDC Shows Strong Weight Reduction
Ascletis (via news release) China Overview Chinese company Ascletis has initiated a global Phase III trial for its oral GLP-1 obesity drug, ASC30. Concurrently, the company announced positive preclinical data for its first-in-class, once... -
Boehringer Ingelheim Initiates Phase II for BI 3034701, a Novel GLP-1/GIP/NPY2 Triple Agonist, Reshaping Obesity Treatment
Life Science Daily News USA Overview Boehringer Ingelheim initiated a Phase II trial in July 2026 for BI 3034701 (NCT07662122), a groundbreaking triple agonist targeting GLP-1, GIP, and the NPY2 receptor, signaling a new direction beyond... -
AI Drug Discovery Cuts Development Time to 18 Months, Insilico Medicine Achieves 99% Cost Reduction for Novel Candidates
BCC Research USA Overview AI is dramatically accelerating drug discovery, shortening the timeline from a decade to under 18 months, with Insilico Medicine identifying a drug candidate for just $2.6 million—a 99% cost saving. This rapid a... -
Scaffold-Aware Transformer with Multi-Scale Attention Accelerates Novel Molecular Design
PMC (Part of MDPI) Switzerland Overview Researchers propose a novel framework for de novo molecular design that integrates a transformer-based generative model and a graph attention network-based predictive model, featuring a scaffold-aw... -
Structure-Aware AI Accelerates Next-Gen Drug Discovery: From 3D Molecular Geometry to Generative Biomolecular Design
Briefings in Bioinformatics | Oxford Academic UK Overview Structure-aware AI systems, leveraging graph neural networks, Transformer-based models, and diffusion-based generative models, are advancing next-generation drug discovery. These ... -
Insilico Medicine Advances AI-Designed Drug to Phase III for IPF, with 31 Candidates Beyond Preclinical Stage
Forbes USA Overview Generative biology, leveraging AI to design drug molecules, proteins, and DNA, is pushing AI-designed candidates into human trials. Insilico Medicine has a Phase III drug for idiopathic pulmonary fibrosis and 31 devel... -
Generative AI Revolutionizes Pharmaceutical Research: Accelerating Drug Discovery from Years to Months
Generative AI in Drug Discovery USA Overview Generative AI is profoundly transforming pharmaceutical research, primarily through de novo drug design, protein structure prediction, and biologics design. It enables the computational genera... -
Generative AI Forges Unprecedented Flavor Molecules, Reshaping the Food Industry
Industry Today USA Overview Generative AI has achieved a significant breakthrough in molecular biology, enabling the de novo design of entirely new flavor molecules that do not exist in nature. This sophisticated system analyzes vast che... -
AI Accelerates Next-Gen Drug Design: From De Novo Protein Creation to Optimized Clinical Trials
SiTech Blog (MIT Technology Review analysis) USA Overview Artificial intelligence is revolutionizing drug discovery by enhancing every stage from protein structure prediction to clinical trial optimization. Generative models like RFdiffu... -
Fujifilm Diosynth Commits $2 Billion to North Carolina Gene Therapy Facility Amid Supply Chain Shifts; India Emerges as Key CDMO Hub
BioSpace Global Overview Fujifilm Diosynth is investing approximately $2 billion in a new gene therapy manufacturing facility in North Carolina, strategically positioning against global supply chain shifts. Catalent, under Novo Holdings,...
